122 / 1851
Summary
•
What we can’t do
–
8000 pt trials in unselected breast cancer
•
What we can do –
–
New continuum for genome-forward approaches
•
Representative model systems in parallel +
•
Small hypothesis-driven trials
–
New strategies for biomarker-driven clinical trials
•
Start broadly (relatively unselected) and learn
•
Be as critical about assays as you are of drugs
–
Novel strategies are good, but so are traditional endpoints –
Overall survival
•
Embrace your lab colleagues, molecular pathologists, and
statisticians!